Effect of the drug indomethacin in the treatment of COVID-19 patients

An academic multicentre open-label single-arm study to record the efficacy of indomethacin among confirmed COVID-19 patients with mild and moderate symptoms

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN11970082

Enrollment

250

Registered

2020-11-20

Start date

2020-08-16

Completion date

Unknown

Last updated

2021-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19 (SARS-CoV-2 infection) Infections and Infestations

Interventions

1. Indomethacin 25 mg two times a day (or 75 mg SR once a day at the discretion of the treating physician) and a proton pump inhibitor 20 mg (or 40 mg at the discretion of the treating physician) for

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Age 21 to 90 years 2. RT-PCR positive 3. Hospitalised patients 4. The case criteria for the study: LFT and KFT normal

Exclusion criteria

Exclusion criteria: 1. Hypersensitivity/allergy to drug 2. Gastritis 3. Recent heart attack 4. Severe asthma 5. Acute kidney Injury 6. Patients on immunosuppressants

Design outcomes

Primary

Measure	Time frame
Patients deteriorating to severe disease measured using the WHO Ordinal Scale for Clinical Improvement every day during the treatment and after the treatment on the sixth day	—

Secondary

Measure	Time frame
1. Kidney function measured using urea and creatinine before the start of the treatment and after the treatment on the sixth day 2. Liver function measured using SGOT and SGPT before the start of the treatment and after the treatment on the sixth day 3. Inflammation measured using C-reactive protein before the start of the treatment and after the treatment on the sixth day	—

Countries

India

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026